Gut-Cleavable Codrug for Local JAK Inhibitor Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK family inhibitors, such as tofacitinib, have systemic adverse effects like infections and malignancies due to widespread drug exposure, necessitating a need for localized delivery in gastrointestinal diseases to enhance safety and efficacy.
Innovation Solution
A codrug compound is designed with a berberine analog linked to a JAK family inhibitor via a covalent linkage that is cleaved in the gastrointestinal tract, releasing both agents locally to enhance therapeutic effects while minimizing systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If JAK family inhibitors are administered systemically to treat rheumatoid arthritis and ulcerative colitis, then therapeutic efficacy is achieved, but severe adverse events including infections and malignancies occur due to widespread drug exposure
Solution Approach 1:
The patent applies local quality by designing a codrug compound that releases JAK family inhibitors specifically in the gastrointestinal tract through enzymatic cleavage by gut flora, rather than systemically throughout the body. This localized release mechanism targets the treatment site (GI tract) while minimizing exposure to other organs, thereby reducing adverse events like infections and malignancies while maintaining therapeutic efficacy for ulcerative colitis
Solution Approach 2:
The patent uses an intermediary approach by incorporating a linker molecule that acts as a carrier between the drug substance and the target site. The linker is designed to be cleaved by gut flora enzymes, serving as a temporary vehicle that delivers the JAK family inhibitor to the gastrointestinal tract and then decomposes, allowing localized release without systemic distribution
2Reliability
If berberine analogs are used to treat gastrointestinal diseases, then therapeutic effects are achieved, but bioavailability is low and therapeutic potential is underutilized
Solution Approach 1:
The patent merges the berberine analog with the JAK family inhibitor in a single codrug compound structure. This combination allows both drugs to be administered together in a controlled-release format, where the berberine analog component is released alongside the JAK inhibitor in the gastrointestinal tract, synergistically enhancing the therapeutic effect while improving overall bioavailability through the coordinated action of both molecules
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The codrug achieves targeted release of JAK inhibitors and berberine analogs in the gastrointestinal tract, providing synergistic treatment for inflammatory diseases with reduced systemic side effects.
Implementation Method 1
a codrug compound which is cleaved in gut. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds for treating gastrointestinal autoimmune diseases, inflammatory diseases and cancers
Data Source
AI summary
The present invention relates to a codrug that cleaved in the gut, preparation therefor, and a use thereof. Specifically, provided is a codrug compound in formula I. Also provided are a method of using the present compound for the treatment of gastrointestinal tract autoimmune diseases, inflammatory diseases, and cancers, as well as a method and an intermediate for preparing the present compound.